Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jade Biosciences, Inc.

NASDAQ: JBIO · Life Sciences · 4 alerts · CIK 1798749

Share price
$15.34Close, Nov 16
Market cap
$1.06B
Shares outstanding
69.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jade Biosciences, Inc. filings on SEC EDGAR ↗

7:14 AM ET 8-K
Clinical Trial Data

Jade Biosciences Clinical Trial Data

Jade Biosciences announced preclinical data for JADE301, an anti-interferon beta monoclonal antibody being developed for dermatomyositis. The data demonstrated high-affinity binding, potent inhibition of downstream signaling, and a differentiated pharmacokinetic profile supporting infrequent subcutaneous dosing. The company expects to initiate a Phase 1 clinical trial in healthy volunteers in Q4 2026, with interim data anticipated in the second half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.